Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Phathom Pharmaceuticals heads into its October 29 earnings report down 28% over the past month, with short sellers retreating slightly but the stock's own history giving bears plenty to work with.
The most telling number in the positioning picture is the earnings track record. Last quarter, the stock fell nearly 25% on the day of results and continued sliding to a five-day loss of almost 28%. The prior print in May was the one exception, delivering a modest 4% gain before fading to a 2.5% loss over the following week. Two of the last two meaningful earnings events have been punishing. With the stock already at $6.81, down from much higher levels earlier this year, the setup going into October 29 is not one that invites casual long exposure.
Short interest has been drifting lower but remains genuinely elevated. Short sellers held roughly 13.9% of the free float as of October 7, down from a peak above 16% in late August but still in territory that warrants attention. The monthly decline of around 13.5% in shares short reflects some covering, yet 9.9 million shares short against a mid-single-digit stock price leaves the position sizeable in dollar terms. The borrow market tells a looser story: cost to borrow has dropped to around 0.52%, down roughly 24% on the week and its lowest level in over six weeks. Availability has widened sharply too, now running at 188% of current short interest versus around 128% a month ago. There is no squeeze pressure here. Plenty of shares remain available for lenders, and the declining cost signals that demand for new shorts is not pressing against supply. The ORTEX short score sits at 70.7, down from above 74 earlier in the week, reflecting the easing but still signalling meaningful bearish structural positioning.
Options flow does not add much alarm. The put/call ratio at 0.09 is just slightly above its 20-day average, with a z-score of 1.3. By the standard of the past year, during which the ratio peaked at 0.15, call open interest still dominates the options market by a wide margin. That is more characteristic of speculative long bets than systematic hedging, an unusual posture given how badly the last print went.
The Street's position is one of cautious support that has been progressively dialled back. Leerink Partners initiated coverage in September with a Market Perform rating and a $10 target, the most conservative fresh view on the stock. Barclays cut its target from $18 to $14 in August while keeping an Overweight, and Guggenheim and Needham both trimmed after the July results while holding Buy ratings. The mean target across the group stands around $20, which implies substantial return potential from the current price. The consensus rating is Hold, a reflection of the two-speed picture where bulls believe in VOQUEZNA's long-term revenue trajectory and bears point to access friction, heavy debt, and execution risk. The EV/EBITDA multiple has compressed by about a full turn over the past 30 days, consistent with the stock's decline. EPS momentum factors rank high, in the 87th to 92nd percentile, suggesting analysts have been lifting estimates even as the price falls.
Medicaid reimbursement data from the Centers for Medicare and Medicaid Services adds concrete texture to the bull case. For the first quarter of 2026, Medicaid dollars reimbursed for Phathom's drug were up 69% on the same quarter a year earlier, with units reimbursed up 64%. Neither dataset has been measured as a leading indicator for the company's reported figures, so this cannot be read as a forecast of the October print. What it does confirm is that the government payer channel is growing meaningfully in volume and value. That sits alongside management's guidance of $310 to $325 million in 2026 revenue, up from $55 million in 2024.
James N. Topper, listed on the SEC's 13D register with an 8.6% stake, remains the most significant registered activist presence on the share register. His most recent filing was an amendment in late 2025, and his stake has not changed from the disclosed level. Frazier Life Sciences Management holds 15.4% as the largest single holder, and BlackRock added around 463,000 shares through to end of September. Stakes are as last disclosed around the 5% threshold, and holders dropping below that level may not file again.
With earnings 21 days away, the question is whether the current mix of easing short pressure, a loosening borrow market, and strong Medicaid growth data is enough to change the pattern of severe post-print selloffs that has defined Phathom's recent history.
See the live data behind this article on ORTEX.
Open PHAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
